§ 285d–7.
(b)
Membership; ex officio members
The Advisory Board shall be composed of twenty appointed members and nonvoting, ex officio members, as follows:
(1)
The Secretary shall appoint—
(A)
twelve members from individuals who are scientists, physicians, and other health professionals, who are not officers or employees of the United States, and who represent the specialties and disciplines relevant to arthritis, musculoskeletal diseases, and skin diseases; and
(B)
eight members from the general public who are knowledgeable with respect to such diseases, including one member who is a person who has such a disease, one person who is the parent of an adult with such a disease, and two members who are parents of children with arthritis.
Of the appointed members at least five shall by virtue of training or experience be knowledgeable in health education, nursing, data systems, public information, or community program development.
(2)
The following shall be ex officio members of the Advisory Board:
(A)
the Assistant Secretary for Health, the Director of NIH, the Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Director of the Centers for Disease Control and Prevention, the Under Secretary for Health of the Department of Veterans Affairs, and the Assistant Secretary of Defense for Health Affairs (or the designees of such officers), and
(B)
such other officers and employees of the United States as the Secretary determines necessary for the Advisory Board to carry out its functions.
(h)
Duties and functions
The Advisory Board shall—
(1)
review and evaluate the implementation of the plan prepared under
section 285d–1(a) of this title and periodically update the plan to ensure its continuing relevance;
(2)
for the purpose of assuring the most effective use and organization of resources respecting arthritis, musculoskeletal diseases and skin diseases, advise and make recommendations to the Congress, the Secretary, the Director of NIH, the Director of the Institute, and the heads of other appropriate Federal agencies for the implementation and revision of such plan; and
(3)
maintain liaison with other advisory bodies for Federal agencies involved in the implementation of such plan, the interagency coordinating committees for such diseases established under
section 285d–4 of this title, and with key non-Federal entities involved in activities affecting the control of such diseases.
([July 1, 1944, ch. 373], title IV, § 442, as added [Pub. L. 99–158, § 2], Nov. 20, 1985, [99 Stat. 852]; amended [Pub. L. 102–405, title III, § 302(e)(1)], Oct. 9, 1992, [106 Stat. 1985]; [Pub. L. 102–531, title III, § 312(d)(7)], Oct. 27, 1992, [106 Stat. 3504]; [Pub. L. 103–43, title VII, § 701(d)], title XX, § 2008(b)(7), June 10, 1993, [107 Stat. 162], 211; [Pub. L. 109–482, title I, § 104(b)(1)(I)], Jan. 15, 2007, [120 Stat. 3693].)